GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
HomeDrugsAleniglipron
Small-molecule GLP-1Investigational · Phase 3

Aleniglipron

Oral small-molecule GLP-1 receptor agonist. Once daily.

Aleniglipron (investigational)·Structure Therapeutics

Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

OverviewDosing & warningsClinical trials

What to know about Aleniglipron

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once daily
Indications

Investigational uses

Aleniglipron (investigational)

Obesity; type 2 diabetes (investigational)

Obesity (investigational)Type 2 diabetes (investigational)

An investigational non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily oral tablet, in the same oral-pill class as orforglipron.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Aleniglipron is investigational. See its registered studies below. Search DailyMed.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Evidence

Clinical trials

6 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
    NCT07654361PHASE3Recruiting3,600 enrolled
  • A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
    NCT07654374PHASE3Recruiting1,100 enrolled
  • A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants…
    NCT06693843PHASE2Completed
Related

Related GLP-1s to compare

Semaglutide
Ozempic, Wegovy, Wegovy HD, Rybelsus
Tirzepatide
Mounjaro, Zepbound
Liraglutide
Victoza, Saxenda
Orforglipron
Foundayo
Questions

Common questions about Aleniglipron

Is Aleniglipron available yet?
No. Aleniglipron is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
All shortagesPrice comparisonCompare drugsProvidersEvidence hubMethodology
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier #5 Product of the DayGLPcompare on LaunchNestFeatured on SaaSCityFeatured on LaunchBuffLeave a review for GLPcompare on Indie Need
230 enrolled
  • A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related…
    NCT06703021PHASE2Completed85 enrolled
  • Aleniglipron Phase 2 Body Composition Study
    NCT07169942PHASE2Active_not_recruiting71 enrolled
  • Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
    NCT07400588PHASE2Active_not_recruiting58 enrolled

    • Source: ClinicalTrials.gov API v2 · as of Oct 8, 2026

    All trials on ClinicalTrials.gov